Het geïntegreerde model is gebouwd voor recombinante moleculen, niet voor aangepaste peptiden in DNA-naar-IND-programma's
De geïntegreerde route wordt gedefinieerd door recombinante expressie, en die definitie, geen gat in de servicedekking, is wat synthetische peptiden daarbuiten plaatst. De programmapagina van Lonza beschrijft één gecoördineerde CMC-workflow die de ontwikkeling van cellijnen mogelijk maakt, proces- en formuleringsontwikkeling, analytische tests en wettelijke documentatie samen door “overdrachten te minimaliseren en alle CMC-activiteiten op één lijn te brengen” (Lonza DNA-naar-IND programmapagina, ongedateerd, opgehaald 2026). Elke stap in die keten begint met een getransfecteerde cel.
De oktober 2026 uitbreiding breidde dezelfde keten uit naar niet-mAb-biologische geneesmiddelen, het toevoegen van bispecifieke antilichamen, Fc-fusie-eiwitten en formuleringen van geneesmiddelen met een hoge concentratie, en het eerder in het proces brengen van de ontwikkeling van formuleringen met een hoge concentratie (Media-advies van Lonza). De genoemde molecuulklassen zijn allemaal recombinante formaten.
De gedefinieerde instappunten van het programma lopen van vectorconstructie en beoordeling van de maakbaarheid via DNA tot toxische medicijnsubstantie of batch van medicijnproducten, DNA om te onderzoeken, master- of productiecelbank, overdracht van een gevestigde cellijn of proces, en bulkmedicijnsubstantie of gezuiverd product, met de optie om volledig geïntegreerd naar de IND te draaien of te pauzeren bij gedefinieerde mijlpalen (Lonza DNA-naar-IND programmapagina, ongedateerd, opgehaald 2026). Een chemisch gesynthetiseerd peptide heeft geen vector, geen cellijn en geen transfectiestap om binnen te komen.
De door de leverancier opgegeven tijdlijnen hebben hetzelfde frame. De mijlpalentabel vermeldt zes maanden vanaf DNA-sequentie tot IND/IMPD, DNA wordt binnen twee maanden vergiftigd en binnen twee maanden wordt de risico's vroegtijdig verminderd 11 weken, met een voetnoot die de claim beperkt tot “van DNA-transfectie tot levering van CMC-modules die IND mogelijk maken. Typische tijdlijnen. Onder voorbehoud van algemene voorwaarden” (Lonza DNA-naar-IND programmapagina, ongedateerd, opgehaald 2026). De klok begint bij transfectie. Voor een volledig chemisch gesynthetiseerd peptide, DNA-transfectie is niet de relevante startmijlpaal.
De twee raamwerken trekken de peptidegrens anders, en het verschil is chemie
Productieroute, producteigenschappen, indicatie en jurisdictie beïnvloeden het regelgevingstraject. Chemie na de keten is één overweging, niet de enkele variabele die bepaalt welk raamwerk van toepassing is.
De twee regimes lopen vervolgens uiteen waar een gemodificeerd peptide terechtkomt. De EMA-richtlijn accepteert beschermde natuurlijke L-aminozuurderivaten, en in gerechtvaardigde gevallen korte peptidefragmenten, als uitgangsmateriaal, maar stelt dat polypeptidefragmenten slechts beperkte verdere GMP-modificatie ondergaan, zoals cyclisatie of conjugatie aan niet-peptidegroepen zoals PEG-ketens, zijn tussenproducten in plaats van uitgangsmaterialen. Het behandelt ook een geactiveerd PEG-derivaat zoals een NHS-ester als tussenproduct zelf (EMA-richtlijn, effectief 1 juni 2026).
FDA trok de 2021 begeleiding in juli 2026. Modificatie of lipidatie alleen sluit een route voor generieke geneesmiddelen niet universeel uit; gelijkheid met het referentieproduct beoordelen, huidige productspecifieke richtlijnen en de daadwerkelijke toepassingsvereisten. Intrekking van de FDA en herziene conceptupdate.
De EMA-richtlijn behandelt relevante vragen over de kwaliteit van synthetische peptiden en conjugingen. De geschiktheid voor het FDA-traject moet afzonderlijk worden beoordeeld voor het voorgestelde product en het referentiegeneesmiddel; the amount of added chemistry does not create a common EMA/FDA exclusion rule.
Wat het onzuiverheids- en specificatierecord feitelijk van een peptide vereist
A peptide’s specification is written from peptide-specific impurity classes and thresholds, not inherited from either adjacent framework. The categories the EMA guideline names are stereoisomers, deletion sequence, truncated sequence and insertion sequence (EMA guideline landing page, effectief 1 juni 2026). The thresholds the EMA points to come from Ph. Eur. general monograph 2034: report an impurity above 0.1%, hierboven identificeren 0.5%, qualify above 1.0%, with no universal numerical limit for unspecified or total peptide-related impurities, which are set product-specifically and justified case by case (EMA-richtlijn, effectief 1 juni 2026).
Groothandel in peptiden The thresholds that do not apply are worth stating plainly, because they are a common source of error. Ik Q3A(R2) sets reporting at 0.05%, identificatie bij 0.10% of 1.0 mg/day and qualification at 0.15% of 1.0 mg/day for a maximum daily dose at or below 2 g/dag (Ik Q3A(R2), current revision). Those numbers are not peptide limits, and the EMA guideline states directly that the Q3A limits “are not applicable” to synthetic peptides.
Conjugation adds attributes that a chain-only specification misses. The EMA guideline requires control of the free unconjugated peptide and the free form of the conjugate moiety, such as free PEG or linker, and states that di-PEGylation, multi-PEGylation and non-site-specific PEGylation products should be adequately controlled (EMA-richtlijn, effectief 1 juni 2026). It also requires that all steps of the intermediate synthesis from the defined starting material be performed under GMP, with full process information in Module 3 Section 3.2.S.2.2.
The specification guideline that excludes synthetic peptides is not the frame to reach for. ICH Q6B defines a specification as a list of tests, references to analytical procedures and acceptance criteria, and its impurity taxonomy is built for recombinant expression: cell substrate-derived, cell culture-derived and downstream-derived (Ik Q6B, Stap 4, 1999). That taxonomy does not transfer to a solid-phase synthesis, where the impurities are enantiomeric and diastereomeric species, partially unprotected amino acids, dipeptides and beta-alanyl impurities (EMA-richtlijn, effectief 1 juni 2026).
Waar een specialist waarde toevoegt: haalbaarheidsbeoordeling voordat de route wordt vastgesteld
The case for an early feasibility check is arithmetic, not preference. Thirty couplings at 99% effective yield give 0.99³⁰, ongeveer 74% cumulative retention before deprotection, inkijk, purification and isolation losses (Pharma's Almanak). A sequence that couples poorly at three positions loses more than the model predicts, and the loss compounds silently until the crude profile is measured.
That is why route selection is a sequence-specific decision rather than a platform default. A 2025 review of therapeutic peptide discovery and synthesis reports that chemical synthesis suits peptides of 50 residues or fewer, where truncated sequences, racemisation and side reactions require HPLC purification, while biological synthesis suits longer sequences but introduces Peptide 1 Fabrikant host-cell proteins, endotoxins and misfolding (Zheng et al., Int. J. Mol. Wetenschap., 2025). The same review notes that minor deviations in amino acid sequence, post-translational modification or impurity profile can critically affect pharmacological activity, pharmacokinetics and immunogenicity.
Scale changes the control points, niet alleen de batchgrootte. Custom peptide synthesis spans milligrams for discovery and assay standards, grams for process development, toxicology and early clinical work, tens to hundreds of grams or around a kilogram per batch for clinical and niche products, and kilograms to multi-kilograms per batch for commercial API, with sequence, modification and purity requirements mattering as much as nominal batch size (Pharma's Almanak, 18 Kunnen 2026). Coupling completeness, deprotection and cleavage behaviour, crude impurity burden, preparative purification loadability and counter-ion or salt form are the points that decide whether a campaign scales, and they are cheapest to test before the route is locked.
Gewijzigd, gelabelde en geconjugeerde peptiden zijn waar het geïntegreerde model stopt
<figure class="blog-chart" style="max-width:640px;margin:1.5rem auto;font-size:12px;line-height:1.3;color:inherit"> <svg viewBox="0 0 560 380" style="max-width: 100%; height: auto; font-family: 'Inter', system-ui, sans-serif; color: #1e293b; --chart-muted: #64748B;" role="img" aria-labelledby="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title 2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc"> <style> /* The renderer puts the chart in an iframe whose element background is black, and the iframe is a different shape to the chart, so the letterbox bands showed as black frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element background, and when the chart is inlined instead this matches nothing. Keep angle brackets out of this block: a style element inside an SVG is parsed as foreign content, so one stray bracket discards every rule in it. */ html, body { background: #ffffff; margin: 0; } @media (prefers-reduced-motion: verminderen) { * { animation: geen !important; overgang: geen !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title">2025 peptide and oligonucleotide CDMO revenue split</title> <desc id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc">peptide and oligonucleotide CDMO revenue split: values for Peptides, Oligonucleotides. 2025 peptide and oligonucleotide CDMO revenue split. donut gegevens: Peptiden 66.7; Oligonucleotides 33.3.Source: Grand View-onderzoek, Peptide & Oligonucleotide CDMO Market 2026.</desc> <text x="280.0" y="29" text-anchor="midden" font-size="18" font-weight="800" fill="currentColor">2025 peptide and oligonucleotide CDMO revenue split</tekst> <path d="M 238.00 93.00 A 92 92 0 1 1 158.23 230.83 L 192.91 210.91 A 52 52 0 1 0 238.00 133.00 Z" fill="#f97316" /> <path d="M 158.23 230.83 A 92 92 0 0 1 238.00 93.00 L 238.00 133.00 A 52 52 0 0 0 192.91 210.91 Z" fill="#38bdf8" /> <text x="238" y="182" text-anchor="midden" font-size="22" font-weight="800" fill="currentColor">100</tekst> <text x="238" y="201" text-anchor="midden" font-size="10" fill="var(--chart-muted, currentColor)">totaal</tekst> <rect x="360" y="96" width="11" height="11" fill="#f97316" /> <text x="378" y="105" font-size="11" fill="currentColor">Peptides 66.7</tekst> <rect x="360" y="124" width="11" height="11" fill="#38bdf8" /> <text x="378" y="133" font-size="11" fill="currentColor">Oligonucleotides 33.3</tekst> <text x="280.0" y="366" text-anchor="midden" font-size="10" fill="var(--chart-muted, currentColor)">Bron: Grand View-onderzoek, Peptide & Oligonucleotide CDMO Market (2026)</tekst> </svg> </figure>
The starting-material logic is where the two regimes separate most sharply. The EMA guideline requires the choice of starting material for the conjugation component to be justified under ICH Q11, and states that activation of a suitable PEG starting material is part of the manufacturing process, so an activated PEG derivative such as an NHS ester may be considered an intermediate rather than a starting material (EMA-richtlijn, effectief 1 juni 2026). It also expects separate documentation for each supplier of the conjugation moiety or linker, and a compiled specification elaborated by the peptide-conjugate manufacturer.
De synthese van aspirine The practical consequence is that a program adding labels, linkers, PEG chains or lipid tails is running a chemistry project alongside a peptide project. De 2025 review’s comparison table makes the split explicit: chemical synthesis enables non-natural amino acids, isotopic labelling and site-specific modifications, while biological synthesis is limited to natural amino acids unless genetic or enzymatic engineering is added (Zheng et al., Int. J. Mol. Wetenschap., 2025). That flexibility is exactly what a recombinant-expression platform cannot absorb. Peptide 2 Fabrikant
De overdracht is een probleem van specificatie en methodeoverdracht, geen tijdlijnprobleem
When a peptide program moves between partners, the transferable asset is the specification and the validated methods behind it, and the governing validation guideline is shared with the biologic route. ik Q2(R2), adopted 1 November 2023 with an error correction on 30 November 2023, applies to analytical procedures used for release and stability testing of drug substances and products, covering assay, potentie, zuiverheid, impurity as a quantitative or limit test, en identiteit, and can be applied phase-appropriately during clinical development (ik Q2(R2), adopted 1 November 2023). Its scope is defined by use case rather than molecule type.
The peptide-specific side of the package is less standardised. The EMA guideline expects full information in Module 3 Section 3.2.S.2.2, including flowchart, process description with all process steps, raw materials and manufacturing process controls, and requires all intermediate synthesis steps from the defined starting material to be performed under GMP (EMA-richtlijn, effectief 1 juni 2026). For a conjugated peptide, that package also carries the conjugation chemistry description and the supplier documentation for each conjugation moiety or linker.
Microbial and endotoxin control are calculated, not fixed. The endotoxin limit is derived as K/M, waar K is 5 EU/kg/hour for most parenteral routes, 0.2 EU/kg/hour for intrathecal and 100 EU/m²/hour for body-surface-area dosing, with M the maximum recommended human dose per kg per hour (USP Algemeen Kapittel <85>, current chapter, opgehaald 2026). Steriliteitstesten onder USP <71> is qualitative: Custom Pna Synthesis it detects viable microbial contamination and does not demonstrate absolute sterility or quantify contamination (USP <71> Steriliteitstesten, harmonisation text). Neither limit travels as a number in a transfer document; both travel as methods and calculations.
The evidence base does not support a benchmark for transfer failure or delay. No primary or peer-reviewed figure for technology-transfer failure rates was located, so the risk is best argued from the regulatory mechanism: de specificatie, the validated methods and the GMP process description are what a receiving site must reproduce, and their completeness determines how much of the program is rebuilt.
Een beslissingsregel voor partnerbeoordelingen
The rule below turns the regulatory boundary into a partnering test. It is written as an if/then list so it can be applied directly in a vendor review.
If the candidate is a chemically synthesized peptide of roughly 50 residues or fewer with no post-chain modification, then a specialist synthesis and analytics partner is the fit, and an integrated recombinant pathway is the wrong entry point.
For a modified construct, identify the relevant conjugation chemistry, site specificity, starting materials and likely impurities. Controls for free PEG or multiple PEG attachments apply when PEG chemistry is involved, not automatically to every isotope label or noncanonical residue.
If the sequence has known difficult segments, then run the feasibility and route check before the route is fixed, omdat 30 couplings at 99% per-step efficiency retain only about 74% of the chain before purification (Pharma's Almanak, 18 Kunnen 2026).
If the program is a recombinant biologic, then the integrated model is the right frame, and the peptide-specific thresholds and conjugation requirements in this article do not apply.
The market context supports treating peptide programs as a distinct buying decision rather than a subset of biologics. The peptide and oligonucleotide CDMO market was USD 3.1 miljard binnen 2025 and is forecast at USD 8.1 miljard door 2033 bij een 12.9% CAGR, with peptides holding 66.7% van 2025 winst (Grand View-onderzoek, 2026 editie, 2025 basisjaar). Both figures come from a report vendor, and the CDMO number covers peptides and oligonucleotides combined. The wider peptide therapeutics market was USD 140.9 miljard binnen 2025, forecast at USD 294.6 miljard door 2033 bij een 8.7% CAGR (Grand View-onderzoek, 2026 editie, 2025 basisjaar). The biologics CDMO market the integrated model sits in is projected at USD 62 billion with an 11.7% CAGR (GlobalData via GlobeNewswire, 14 oktober 2026). All three are report-vendor models. Oligopeptide Synthesis
Veelgestelde vragen
Zijn de tijdlijnen die Lonza heeft aangekondigd van toepassing op een peptideprogramma??
Nee, because the clock those timelines measure starts at DNA transfection, and the formats named in the same material are recombinant: monoclonal antibodies, bispecifics and Fc-fusion proteins (Lonza DNA-naar-IND programmapagina, ongedateerd, opgehaald 2026). A chemically synthesized peptide never passes through that step, so the schedule is not a benchmark a peptide team can borrow. What transfers between the two is the regulatory destination, not the route or the calendar.
Kan een specialist een programma naar de IND brengen zonder geïntegreerde aanbieder??
Ja. The Module 3 en Q2(R2) obligations do not change with the size of the partner, so the difference is not what gets filed but who holds the specification and the validated method set at filing. A specialist can hold both, provided the discovery to development peptide handoff is documented as a controlled transfer rather than an informal one. What an integrated provider adds is convenience of coordination, not a regulatory category the specialist cannot occupy.
Wat als een programma al halverwege een geïntegreerd pad is??
Transfer the specification, the methods and the comparative batches instead of restarting. Restarting discards the analytical history that supports the specification, and rebuilding it costs more than moving it. The transfer package is the unit of work: product-specific limits, validated release and stability methods, and the process description that shows where the defined starting material sits.
Conclusie
A peptide program does not inherit the small-molecule impurity framework, and it does not inherit the biologic one. Ik Q3A(R2) excludes peptides, ICH Q6B excludes synthetic peptides, and the EMA guideline effective 1 juni 2026 supplies the peptide-specific framework in their place, with Ph. Eur. 2034 thresholds and product-specific limits. That is the structural fact behind the partnering question, and it is independent of any vendor’s timeline.
The integrated DNA-to-IND model is a coherent answer to a recombinant problem. Its named molecule classes are mAbs, bispecifics and Fc-fusion proteins, its entry points begin at vector construction, and its clock starts at DNA transfection. A chemically synthesized peptide has none of those inputs, so the fit question is answered before cost or speed enters the discussion.
The next step is a feasibility assessment on the specific sequence, run before the route is fixed. Sequence-level coupling risk, modification chemistry, scale target and the applicable specification framework determine whether a specialist partner is the right choice, and the arithmetic of per-step yield makes that assessment cheapest at the earliest stage.
